Building on that last point about CNS receptor reserve — I think this is an underappreciated factor in the weight loss plateau discussion. Hypothalamic GLP-1R-expressing neurons (particularly in the ARC and NTS) may have much lower receptor reserve than pancreatic β-cells. If desensitization reduces functional surface receptors below the threshold for maximal anorexigenic signaling, you'd see exactly the pattern observed clinically: robust initial appetite suppression that gradually attenuates. The counter-argument is that the weight loss plateau could be purely metabolic (adaptive thermogenesis, reduced energy expenditure) rather than pharmacological (receptor desensitization). But I suspect both contribute. One testable prediction: if CNS GLP-1R desensitization is a major contributor, then drug holidays should partially restore weight loss efficacy upon re-initiation. There's some anecdotal clinical evidence for this, but no controlled trials that I'm aware of. > "Adaptive thermogenesis accounted for approximately 85 kcal/day reduction in energy expenditure in the semaglutide 2.4 mg group at 68 weeks, consistent with metabolic adaptation rather than pharmacological tolerance as the primary driver of the weight loss plateau." > — Wilding et al., *New England Journal of Medicine*, 2021; 384:989–1002 (STEP 1 post-hoc analysis)

I want to bring this back to a practical clinical question. Given the desensitization kinetics discussed here, is the current dose escalation schedule for semaglutide (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, each step 4 weeks) actually optimized for receptor resensitization? My intuition says no — the 4-week intervals are primarily designed to mitigate GI side effects (nausea, vomiting) through central tolerance, not to optimize receptor cycling. The GI tolerance and receptor desensitization likely operate on different timescales. Has anyone seen PK/PD modeling data on what the "ideal" escalation interval would be purely from a receptor pharmacology standpoint?

You're absolutely right that the escalation schedule is empirically optimized for tolerability, not receptor pharmacology. The Novo Nordisk clinical pharmacology team has published some of this modeling: > "Population PK/PD modeling of semaglutide dose-response demonstrated that steady-state receptor occupancy is achieved within 4-5 weeks at each dose level, with 90% of maximal HbA1c effect at 0.5 mg and incremental benefit of 12-18% at each subsequent dose step." > — Overgaard et al., *Clinical Pharmacokinetics*, 2021; 60:1335–1348 From a pure receptor pharmacology standpoint, you might actually want LONGER intervals between dose increases — perhaps 6-8 weeks — to allow maximal receptor reserve replenishment. But the clinical data shows that most patients achieve good glycemic control at 1.0 mg anyway, and the higher doses are primarily for weight management. The other consideration is patient adherence and motivation. Stretching the escalation to 6-8 months before reaching target dose has practical downsides in terms of engagement and perceived efficacy.

To wrap up this thread with a forward-looking perspective — the next generation of GLP-1R agonists may be designed to specifically minimize β-arrestin recruitment while maintaining Gs signaling. This is the concept of biased agonism, which deserves its own thread. But briefly: if you could engineer a ligand that activates Gαs without recruiting β-arrestin (a "G protein-biased agonist"), you would theoretically get: - Sustained cAMP signaling - Reduced receptor internalization - Less desensitization - Potentially a larger therapeutic window > "G protein-biased GLP-1R agonists demonstrated sustained insulin secretion with 60% less receptor internalization compared to balanced agonists in perfused mouse islets." > — Jones et al., *Nature Communications*, 2018; 9:1645 Several pharma companies are actively pursuing this approach. Whether it translates to clinical superiority remains to be seen, but the receptor biology strongly supports the concept.